World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT02955212
Date of registration: 02/11/2016
Prospective Registration: Yes
Primary sponsor: AbbVie
Public title: A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
Scientific title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
Date of first enrolment: January 3, 2018
Target sample size: 338
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02955212
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 3
Countries of recruitment
Brazil China Korea, Republic of
Contacts
Name:     AbbVie Inc.
Address: 
Telephone:
Email:
Affiliation:  AbbVie
Key inclusion & exclusion criteria

Inclusion Criteria:

- Diagnosis of RA for = 3 months who also fulfill the 2010 American College of
Rheumatology (ACR)/ European League Against Rheumatism (EULAR) classification criteria
for RA.

- Participants have been receiving csDMARD therapy = 3 months and on a stable dose for =
4 weeks prior to the first dose of study drug.

1. Participants must have failed (lack of efficacy) at least one of the following:
methotrexate (MTX), sulfasalazine, or leflunomide.

2. The following csDMARDs are allowed: oral or parenteral MTX, sulfasalazine,
hydroxychloroquine, chloroquine, and leflunomide.

3. A combination of up to two background csDMARDs is allowed except the combination
of MTX and leflunomide.

- Participant meets both of the following disease activity criteria:

1. = 6 swollen joints (based on 66 joint counts) and = 6 tender joints (based on 68
joint counts) at Screening and Baseline Visits; and

2. High-sensitivity C-Reactive Protein (hsCRP) = 3 mg/L at Screening

- Participants with prior exposure to at most one biological disease-modifying
anti-rheumatic drugs (bDMARD) may be enrolled (up to 20% of total number of subjects).
Specifically, prior to enrollment:

1. Participants with limited exposure to bDMARD (< 3 months) OR

2. Participants who are responding to a bDMARD therapy but had to discontinue due to
intolerability (regardless of treatment duration).

- Participants must have discontinued bDMARD therapy prior to the first dose of study
drug.

Exclusion Criteria:

- Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
tofacitinib, baricitinib, and filgotinib).

- Participants who are considered inadequate responders (lack of efficacy) to bDMARD
therapy as defined by the Investigator.

- History of any arthritis with onset prior to age 17 years or current diagnosis of
inflammatory joint disease other than RA (including but not limited to gout, systemic
lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing
spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap
connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia
[currently with active symptoms]. Current diagnosis of secondary Sjogren's Syndrome is
permitted.



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis (RA)
Intervention(s)
Drug: Upadacitinib
Drug: Placebo
Primary Outcome(s)
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 [Time Frame: Baseline and Week 12]
Secondary Outcome(s)
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12 [Time Frame: Week 12]
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 [Time Frame: Baseline and Week 12]
Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) at Week 12 [Time Frame: Week 12]
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 [Time Frame: Baseline and Week 12]
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 [Time Frame: Baseline and Week 12]
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1 [Time Frame: Baseline and Week 1]
Change From Baseline in Disease Activity Score Based on CRP (DAS28 [CRP]) at Week 12 [Time Frame: Baseline and Week 12]
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 [Time Frame: Baseline and Week 12]
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12 [Time Frame: Week 12]
Secondary ID(s)
M15-557
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 06/08/2020
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT02955212
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history